Macquarie 21-Jan-14
Weekly US testosterone prescription data show the 17th consecutive week of negative growth and the 7th consecutive week of falls of 5%pa or more, the broker notes. Macro drivers remain challenging and the broker continues to see risks, albeit the Lilly quarterly result, due next week, may provide a positive catalyst.
Underperform and $2.43 target retained.
Underperform
- Forums
- ASX - By Stock
- the macquarie view
ACR
acrux limited
Add to My Watchlist
0.00%
!
1.4¢

Macquarie 21-Jan-14 Weekly US testosterone prescription data...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.934M |
Open | High | Low | Value | Volume |
1.4¢ | 1.5¢ | 1.4¢ | $2.474K | 176K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 215 | 1.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.4¢ | 214 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
6 | 2281974 | 0.014 |
5 | 2470000 | 0.013 |
7 | 1793000 | 0.012 |
1 | 454545 | 0.011 |
5 | 1302500 | 0.010 |
Price($) | Vol. | No. |
---|---|---|
0.015 | 925136 | 6 |
0.016 | 385714 | 2 |
0.017 | 508041 | 2 |
0.018 | 560861 | 2 |
0.019 | 176000 | 2 |
Last trade - 15.48pm 16/09/2025 (20 minute delay) ? |
Featured News
ACR (ASX) Chart |